Proximagen Neuroscience signs exclusive in-licensing agreement with Northwestern University (Chicago)
On May 22, 2006, AIM-listed Proximagen Neuroscience Plc announced that it had signed an exclusive in-licensing agreement with Northwestern University in Chicago for a platform of drug candidates for the treatment of a range of neuropsychiatric conditions and movement disorders.
Proximagen Neuroscience is a drug discovery and development company focused on neurodegenerative diseases.